Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Income (2022 - 2025)

Historic Net Income for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$38.3 million.

  • Stoke Therapeutics' Net Income fell 4508.89% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 13826.23%. This contributed to the annual value of -$88.7 million for FY2024, which is 1538.26% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Net Income is -$38.3 million, which was down 4508.89% from -$23.5 million recorded in Q2 2025.
  • Stoke Therapeutics' Net Income's 5-year high stood at $112.9 million during Q1 2025, with a 5-year trough of -$38.3 million in Q3 2025.
  • Its 4-year average for Net Income is -$16.3 million, with a median of -$25.7 million in 2024.
  • Data for Stoke Therapeutics' Net Income shows a peak YoY increase of 52799.35% (in 2025) and a maximum YoY decrease of 4508.89% (in 2025) over the last 5 years.
  • Over the past 4 years, Stoke Therapeutics' Net Income (Quarter) stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 258.95% to -$38.3 million in 2025.
  • Its Net Income was -$38.3 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $112.9 million in Q1 2025.